Q/C Technologies Swings to Wider Loss, Names New CFO After License Termination
QCLS sits 16% above its 52-week low of $2.5 on light trading volume (0.1× avg).
Summary
Q/C Technologies posted a wider Q2 loss of $6.6M, took a $3.2M impairment on its terminated LightSolver license, and appointed Todd Fagan as CFO. Liquidity remains adequate for 12 months.
Key Events · Earnings and Guidance · QCLS
-
Q2 Net Loss Widens to $6.6M
Net loss attributable to common stockholders was $6.5M, or $(0.79) per share, compared to $2.8M, or $(51.10) per share, in Q2 2025. The loss was driven by a $3.2M impairment of the LightSolver technology license and a $2.4M increase in stock-based compensation.
-
LightSolver License Impairment
The company recorded a $3,177,999 impairment charge in Q2 2026 after terminating its LightSolver license agreement on June 26, 2026. This follows the 8-K filed July 2, 2026, and removes future milestone payment obligations.
-
CFO Transition
Ian Rhodes was terminated as Interim CFO and Todd Fagan was appointed CFO effective August 11, 2026. Fagan's employment agreement includes a $240,000 base salary, up to 50% bonus, and three months' severance.
-
Stock-Based Compensation Surge
Stock-based compensation expense jumped to $2.37M in Q2 2026 from $0.10M in Q2 2025, primarily due to immediately-vesting stock options granted to the Board of Directors and a consulting agreement.
Analysis · QCLS · Life Sciences
Q/C Technologies reported a net loss of $6.6 million for Q2 2026, more than triple the prior-year loss, driven by a $3.2 million impairment charge from terminating its LightSolver license and a surge in stock-based compensation. The company also replaced its interim CFO with Todd Fagan, effective August 11, 2026. Despite the losses, management affirmed a 12-month liquidity runway with $11 million in cash and marketable securities.
At the time of this filing, QCLS was trading at $2.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22.7M. The 52-week trading range was $2.50 to $12.24. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.